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Selective MSCs differentiation protocol into pancreatic beta cells was conducted in the present study
using exendin-4 and TGF-beta. Differentiated and undifferentiated MSCs were assessed in experimental
type I diabetes in rats. Ninety female white albino rats were included in the study and divided equally
(n¼15/group) into 6 groups: healthy control, healthy control rats received acellular tissue culture
medium, diabetic rats, diabetic rats received acellular tissue culture medium, diabetic rats received
undifferentiated MSCs and diabetic rats received differentiated MSCs. Therapeutic efﬁcacy of un-
differentiated versus differentiated MSCs was evaluated via assessment of quantitative gene expressions
of insulin1, insulin 2, Smad-2, Smad-3, PDX-1, PAX-4, neuroD. Blood glucose and insulin hormone levels
were also assessed. Results showed that quantitative gene expressions of all studied genes showed
signiﬁcant decrease in diabetic rat groups. Use of undifferentiated and differentiated MSCs led to a
signiﬁcant elevation of expression levels of all genes with more superior effect with differentiated MSCs
except smad-2 gene. As regards insulin hormone levels, use of either undifferentiated or differentiated
MSCs led to a signiﬁcant elevation of its levels with more therapeutic effect with differentiated MSCs.
Blood glucose levels were signiﬁcantly decreased with both undifferentiated and differentiated MSCs in
comparison to diabetic groups but its levels were normalized 2 months after injection of differentiated
MSCs. In conclusion, use of undifferentiated or differentiated MSCs exhibited signiﬁcant therapeutic
potentials in experimental type I diabetes in rats with more signiﬁcant therapeutic effect with the use of
differentiated MSCs.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type I diabetes mellitus (DM) is a prevalent disease affecting
millions of people with serious morbid complications. Efﬁcient
glycemic control with exogenous insulin therapy is the corner-
stone of treatment which imposes a great burden to most patients.
Isolated beta cells or whole intact pancreas transplantation is an
alternative treatment for patients with type I DM. However, the
shortages of cadaveric pancreas and the need to immune-sup-
pressive drugs are limiting factors [15].B.V. This is an open access article u
ical Biochemistry, Faculty of
Wassef),
y69@yahoo.com (D. Sabry),
yahoo.com (A.M. Abbas),Recent progress in regenerative therapies has focused attention
on generation of surrogate β cells from mesenchymal stem cells
derived adult tissues [4]. Bone marrow-derived mesenchymal
stem cells (BM-MSCs) are multipotent that have efﬁcient trans-
differentiation potentials into mesodermal, endodermal, and ec-
todermal lineages [7,13]. BM-MSCs are good sources for genera-
tion of large numbers of autologous β cells circumventing the
major limitations of cadaveric organs availability and allogenic
rejection [2,11].
Exendine-4 is a novel insulinotropic peptide and a long acting
analog of glucagon-like peptide-1 (GLP-1). It interacts with endo-
crine pancreatic islet GLP-1 receptors, inducing a stimulatory ef-
fect on insulin secretion. Exogenous exendin-4 has shown to in-
duce insulin-positive/endocrine differentiation in pancreatic exo-
crine AR42J cells [14,21].
The co-application of exogenous exendin-4 and, speciﬁcally,
low-dose exogenous transforming growth factorβ-1 (TGFβ-1) led
to a dramatic 20-fold increase in insulin mRNA levels, supporting ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
PCR primers of insulin 1, insulin 2, smad-2, smad-3, PDX-1, PAX4, and Neuro-D.









SMAD family member 2 (Smad2)
5′-AGCCGCCCGAAGGGTA-3′
5′-CAAGACTGGTGTCTCCACCC-3′
NM_013095.3 Rattus norvegicus SMAD
family member 3 (Smad3)
5′-GTTAAAAGCGAAGTTCGGGCG-3′
5′-CTTGGTGTTCACGTTCTGCG-3′
NM_022852.3 Rattus norvegicus pan-





paired box 4 (Pax4)
5′- GACGGTCTCAGCAGTGTGAA-3′
5′- GGGGACTAGGAAGAGCTGGA-3′
NM_019218.2 Rattus norvegicus neu-
ronal differentiation 1 (Neurod1)
5′- AATCATACAGCGAGAGCGGG-3′
5′- GCTGGGACAAACCTTTGCAG-3′





M.A. Wassef et al. / Biochemistry and Biophysics Reports 5 (2016) 468–475 469novel synergistic and codependent relationship between exendin-
4 signaling and TGF-isoform signaling [20]. Exogenous TGF-beta1
and exendin-4 each individually enhanced both insulin and glu-
cagon differentiation dose-dependently. However, when com-
bined there was an additive effect to a 4.5-fold increase in insulin-
positive differentiation [18]. The pancreatic lineage differentiation
was evaluated via assessment of gene expressions of insulin-1,
insulin-2, PDX-1, PAX-4 and NeuroD [12].
The present study was conducted to assess the therapeutic
efﬁcacy of undifferentiated versus differentiated mesenchymal
stem cells in experimental type I diabetes mellitus in rats. Selec-
tive differentiation protocol using TGF-beta and exendin-4 was
implemented.2. Materials and methods
2.1. Preparation of BM-derived MSCs
Bone marrow was isolated and propagated according to the
standard described method [1]. Bone marrow was harvested by
ﬂushing the tibiae and femurs of 6-week-old white albino ratsFig. 1. A: Spindle shaped MSCs at one week culture, B: MSCs at 2 weeks culture. C: Hom
ﬂuorescent labeled differentiated MSCs into pancreatic like cells in rat pancreas.with Dulbecco's modiﬁed Eagle's medium (DMEM, GIBCO/BRL)
supplemented with 10% fetal bovine serum (GIBCO/BRL). Nu-
cleated cells were isolated with a density gradient [Ficoll/Paque
(Pharmacia)] and resuspended in complete culture medium sup-
plemented with 1% penicillin–streptomycin (GIBCO/BRL). Cells
were incubated at 37 °C in 5% humidiﬁed CO2 for 12–14 days as
primary culture or upon formation of large colonies. When large
colonies developed (80–90% conﬂuence), cultures were washed
twice with phosphate buffer saline (PBS) and the cells were
trypsinized with 0.25% trypsin in 1 mM EDTA (GIBCO/BRL) for
5 min at 37 °C. After centrifugation, cells were resuspended with
serum-supplemented medium and incubated in 50 cm2 culture
ﬂask (Falcon). Cells were identiﬁed as being MSCs by their mor-
phology, adherence, and their power to differentiate into osteo-
cytes [9] and chondrocytes [16].
2.2. BM-derived MSCs differentiation into islet like cell clusters (ICC)
MSCs at passage 2 was induced with L-DMEM (4.5 mmol/L),
glucose 5%, FBS, nicotinamide (10 mmol/L) and β-meracptoethanol
(2.5 mmol/L) for 24 h. Re-inductionwas conducted for 10 h with the
same culture medium without FBS and with L-DMEM (25 mmol/L).
Maintenance of ICC was conducted for 3 weeks with L-DMEM
(25 mmol/L), glucose 5%, without FBS, nicotinamide (10 mmol/L), β-
meracptoethanol (2.5 mmol/L), exendin-4 (10 pmol/L) and TGFβ-1
(100 pmol/L). Smad2 gene expression was assessed in the un-
differentiated and in the differentiated MSCs in vitro.
2.3. Labeling stem cells with PKH26
Undifferentiated and differentiated MSCs cells were labeled
with PKH26 according to the manufacturer's recommendations,
(Sigma, Saint Louis, Missouri, USA). The procedure involved use of
2 mL staining dye containing ﬁnal concentrations of 210–6 M of
PKH26 and 1107 cells/mL. PKH26 is a ﬂuorescent labeling dye.
Labeling occurs by partitioning of the lipophilic dye into cell
membranes. Labeling intensity is a function of both dye con-
centration and cell concentration and is not saturable. Incubation
of the cell/dye suspension for 1–5 min with periodic mixing was
conducted. The staining was stopped by adding an equal volume
(2 mL) of a protein solution (e.g., 1% BSA) and incubation for 1 mining of PKH26 ﬂuorescent labeled undifferentiated MSCs in rat pancreas. D: PKH26
Fig. 2. Flow-cytometric characterization analysis of bone marrow- derived MSCs. Cells were uniformly positive for CD29, and CD44 and negative for CD34 and CD45.
Fig. 3. Unstained rat bone marrow MSCs during differentiation. A: MSCs started to
form cell clusters after 10 days of differentiation (X200). B: collected cell clusters
after 20 days of differentiation (X200). C: well deﬁned cell clusters with spheroid
conﬁguration were formed after 25 days of differentiation (X200).
M.A. Wassef et al. / Biochemistry and Biophysics Reports 5 (2016) 468–475470to allow binding of excess dye. Visualization of stained cells was
conducted using Nikon's SMZ25 (USA) ﬂuorescent microscopy
using PE ﬁlter for PKH26.
Cells were injected intravenously into rat tail vein. After one
month, pancreatic tissue was examined with a ﬂuorescence mi-
croscope to detect the cells stained with PKH26.
2.4. Preparation of animal groups
The present study was conducted on ninety female rats inbred
strain (Cux1: HEL1) of matched age and weight (6 months to 1
year and 120150 gm). Animals were inbred in the experimental
animal unit, Faculty of Medicine, Cairo University. Rats were
maintained according to the standard guidelines of Institutional
Animal Care and Use Committee and after Institutional Review
Board approval. Animals were fed a semi-puriﬁed diet thatcontained (gm/kg): 200 casein, 555 sucrose, 100 cellulose, 100 fat
blends, 35 vitamin mix, and 35 mineral. Diabetes type I was in-
duced in the relevant rat groups using a single intra-peritoneal
injection of streptozotocin dissolved in 0.1 M sodium citrate buffer,
pH 4.5, at a dose of 50 mg/kg. Induction of diabetes was conﬁrmed
by assessment of blood glucose after 72 h of streptozotocin in-
jection. Rats with blood glucose above 200 mg/dL were considered
to be diabetic.
Animals were divided equally into the following groups:
Group 1: Included 15 normal healthy rats that received the
standard diet i.e. negative control group.
Group 2: Included normal healthy rats 15 rats that received the
standard diet and acellular tissue culture medium.
Group 3: Included 15 rats that received streptozotosin to induce
type I diabetes mellitus. i.e. diabetic control (positive control group).
Group 4: Included 15 diabetic rats received acellular tissue
culture media.
Group 5: Included 15 diabetic rats that received un-
differentiated MSCs stained with PKH26 red ﬂouresence (3106
cells intravenously, once) [2].
Group 6: Included 15 diabetic rats that received selectively
differentiated MSCs into pancreatic progenitor cells stained with
PKH26 red ﬂouresence (102103 cells intravenously, once) [7].
Three rats died in the control diabetic group and 5 rats died in
the control diabetic injected with acellular group. All rats were
sacriﬁced at the end of the third month. Blood samples were
collected at the ﬁrst, second and the third month to assess blood
glucose and insulin levels by ELISA.
2.5. Real-time quantitative analysis for insulin1, insulin2, Smad-2,
Smad-3, PDX-1, PAX-4, neuroD and GAPDH genes in pancreatic
tissues
Total RNA was extracted from pancreatic tissue homogenate
using RNeasy puriﬁcation reagent (Qiagen, Valencia, CA). cDNA
was generated from 5 μg of total RNA using RT reagent kit (Applied
biosystems, catalog number 4306736). Real-time qPCR ampliﬁca-
tion and analysis were performed using SYBRs Green PCR Master
Mix Reagents Kit (Catalog Number 4309155) and Applied Biosys-
tem Instrument with software version 3.1 (StepOne™, USA). The
qPCR assay with the primer sets were optimized at the annealing
temperature (Table 1).
2.6. Analysis of pancreatic tissue pathology
Pancreatic tissue samples were collected into PBS and ﬁxed
overnight in 40 g/L paraformaldehyde in PBS at 4 °C. Serial 5-μm
sections of the pancreatic tissues were stained with hematoxylin
and eosin (HE) and were examined histo-pathologically.
2.7. Statistical analysis
Data were coded and entered using the statistical package SPSS
Fig. 4. Rat bone marrow MSCs during differentiation stained with DTZ: A: MSCs started to form cell clusters after 10 days of differentiation (X200). B: collected cell clusters
after 20 days of differentiation (X200). C, D, and E: well deﬁned cell clusters with spheroid conﬁguration were formed after 25 days of differentiation (X200).
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viation. Comparisons between groups were done using analysis of
variance (ANOVA) with multiple comparisons post hoc test in
normally distributed quantitative variables while nonparametric
Kruscal-Wallis test and Mann-Whitney test were used for non-
normally distributed quantitative variables by pearson correlation.
P values less than 0.05 were considered as statistically signiﬁcant.3. Results
Isolated and cultured MSCs were identiﬁed by their character-
istic ﬁbroblast shape after 1 and 2 weeks (Fig. 1A and B). Me-
senchymal stem cells labeled with PKH26 ﬂuorescent dye detected
in the pancreatic tissue, conﬁrming homing into the injured pan-
creatic tissues (Figs. 1C and D). Flow-cytometric characterization
revealed that MSCs were uniformly positive for CD29, and CD44
and negative for CD34 and CD45 (Fig. 2). Morphological change of
unstained and stained (dithizone stain; DTZ) rat bone marrow
MSCs during differentiation showed that MSCs started to form cell
clusters after 10 days of differentiation, collected cell clusters after
20 days and well deﬁned cell clusters with spheroid conﬁguration
were formed after 25 days of differentiation (Figs. 3 and 4).
Smad-2 gene expression in cultured MSCs showed signiﬁcant
increase in the undifferentiated MSCs versus the differentiated
MSCs in culture. (Fig. 5).
As regards blood glucose levels, use of either undifferentiated
or differentiated MSCs exhibited signiﬁcant decrease in blood
glucose levels as compared to diabetic rats, whereas, the levelswere still higher than healthy control animals except two months
after injection of differentiated MSCs where blood glucose levels
were normalized (Table 2 and Fig. 6).
Insulin levels were signiﬁcantly decreased in diabetic rat
groups. Use of either undifferentiated or differentiated MSCs led to
a signiﬁcant increase and normalization in insulin levels except
after the 1st month of injection of undifferentiated MSCs (Table 3
and Fig. 7).
Insulin 1 and Insulin 2 gene expressions showed signiﬁcant
decrease in diabetic rat groups. Use of undifferentiated MSCs led to
a signiﬁcant elevation in insulin genes expression but their levels
were still lower than control group. Use of differentiated MSCs led
to a signiﬁcant elevation and normalization of insulin genes ex-
pression as compared in control rat group (Fig. 8).
As regards SMAD-2, SMAD-3, PDX-1, PAX-4 and NeuroD gene
expressions, their levels showed signiﬁcant decrease in diabetic rat
groups. Use of undifferentiated and differentiated MSCs led to a
signiﬁcant elevation of expression levels of all genes with more
superior effect with differentiated MSCs (Fig. 9).4. Discussion
As a paradigm for stem cell therapy, we have studied the
combined use of exendin-4 and TGFβ1 to induce selective lineage
differentiation of MSCs into pancreatic progenitor beta cells. In the
in vitro study, results showed that gene expression levels of smad2
were signiﬁcantly elevated in the undifferentiated MSCs. However,
in the differentiated MSCs there was signiﬁcant down regulat-
Fig. 5. Smad2 relative gene expression in the undifferentiated and the differ-
entiated MSCs in vitro.
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expression. The same pattern of genes expression was observed in
the in vivo study for smad2 and smad3.
Yew et al. [20] stated that the acquisition of a β-cell phenotype,
including insulin mRNA and protein expression, islet amyloid
polypeptide (IAPP) expression, and pdx-1 expression, was de-
pendent on smad2 pro-endocrine differentiation in the initial
stages of differentiation followed by smad3 induced maturation
and expression of β-cell–speciﬁc markers such as PDX1 [6,20].
Based on these data, it appears that smad3 may support matura-
tion of β-cells and inhibition of proliferation but only after smad2
has initiated a pro-endocrine differentiation program.
Results of the present study showed that use of either un-
differentiated or differentiated MSCs led to a signiﬁcant increase in
insulin 1, insulin 2 genes, insulin hormone levels and genetic
markers of beta cell maturation as PDX-1, PAX-4 and neurogenin D.
Differentiated MSCs was superior to undifferentiated MSCs re-
garding all of the studied parameters. Similar ﬁndings were re-
ported by other studies. Yew et al. [20,21] reported that exendin-4Table 2


















89.275.4 415.2731.2 87.676.3 412732induce insulin-positive/endocrine differentiation in rat AR42J
pancreatic epithelial cells. Insulin-positive differentiation was in-
itiated by exendin-4 which induced down-regulation of smad2
and up-regulation of smad3 gene expression. The latter appears to
be dependent on endogenous transforming growth factor (TGF)-β
release by the AR42J cells and could be a mechanism to promote
β-cell maturation. The co-application of exogenous exendin-4 and
low-dose exogenous TGF-β1 led to a dramatic 20-fold increase in
insulin gene expression, supporting a novel codependent sy-
nergistic relationship between exendin-4 signaling and TGF-β
isoform signaling. More recently, Tamaki et al. [17] stated that
glucagon-like peptide 1 (GLP-1) and its mimetic compound, ex-
endin-4, exert their functions through multiple pathways, acting
on the brain to induce satiety and potentiating glucose-stimulated
insulin secretion. In addition, GLP-1 also has proliferative and anti-
apoptotic effects on rodent beta-cells. Not only regulating re-
plication and apoptosis of pre-existing b-cells, GLP-1 and exendin-
4 also induce neogenesis of b-cells both in vivo and in vitro.
Moreover, Zhou et al. [23] studied the effects of exendin-4 (Ex-4)
on MSC. The authors found that after treatment with Ex-4, MSC
displayed a higher proliferative capacity, increased expression of
C-X-C motif receptor 4 (CXCR4) and an enhanced migration re-
sponse. Moreover, Ex-4 preserved mitochondrial function through
scavenging ROS and balancing the expression of anti- and pro-
apoptotic proteins, leading to increased cell survival. Moreover, the
authors proved that the PI3K/Akt pathway is partly responsible for
Ex-4-mediated MSC growth, mobilization and survival. These
ﬁndings provide an attractive method of maximizing the effec-
tiveness of MSC-based therapies in clinical applications.
Our ﬁndings agreed with previous studies that showed the
efﬁcient protocol used in this study for trans-differentiation of
bone marrow-derived MSCs into beta cells. The differentiated cells
expressed nestin, pancreatic duodenal homeobox-1 (PDX-1),
Neurogenin3, Pax4, insulin and glucagon [3,5,10].
PDX-1 gene is a transcriptional activator of several genes, in-
cluding insulin, somatostatin, glucokinase, islet amyloid polypep-
tide, and glucose transporter type 2. The encoded nuclear protein
is involved in the early development of the pancreas and plays a
major role in glucose-dependent regulation of insulin gene ex-
pression. Defects in this gene are a cause of pancreatic agenesis,
which can lead to early-onset insulin-dependent diabetes mellitus
(NIDDM), as well as maturity onset diabetes of the young type 4
(MODY4) [19]. PDX-1 is a master switch gene that control gene
expression cascade of all other transcription factors responsible for
endocrine neogenesis [22]. These facts could explain our results
that demonstrated signiﬁcant elevation of PDX-1 gene expression
and other pancreatic genes: PAX-4, insulin-1, insulin2 and neuroD








Fig. 6. Blood glucose levels (mg/dL) in the studied rat groups after 1st, 2nd and 3rd months.
Table 3













Insulin levels after 1st
month
40.272.9 770.5 34.572.8 7.570.4 20.372.1 30.872.7
Insulin levels after 2nd
month
39.973.0 4.970.4 34.772.9 4.670.4 29.872.7 43.973.2
Insulin levels after 3rd
month
37.773.1 3.570.5 39.673.0 3.670.5 31.173.2 85.1711.3
Fig. 7. Insulin hormone levels (IU/mL) in the studied rat groups after 1st, 2nd and 3rd months.
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Fig. 8. Relative gene expression of insulin-1 and insulin-2 in the pancreatic tissues of the studied rat groups.
Fig. 9. Relative gene expression of smad2, smad3, PDX-1, PAX-4 and neuroD in the pancreatic tissues of the studied rat groups.
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Use of undifferentiated or differentiated MSCs exhibited sig-
niﬁcant therapeutic potentials in experimental type I diabetes in
rats with more signiﬁcant therapeutic value with the use of differ-
entiated MSCs. Further studies are recommended for use of differ-
entiated MSCs in experimental diabetes with long term follow up to
ensure safety and efﬁcacy for justiﬁcation of clinical trials.Appendix A. Transparency document
Transparency document associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.bbrep.2016.02.001.References
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